Literature DB >> 28874375

Subinhibitory Dalbavancin Attenuates Exotoxin Production from Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus In Vitro.

Sarah E Hobdey1,2, Eva J Katahira2, Pamela Dockstader3, Stephen M Davidson3, Laura Bond4, Devin D Bolz3,2, Amy E Bryant3,2, Dennis L Stevens3,2,5.   

Abstract

This study investigated the effects of subinhibitory doses of the lipoglycopeptide antibiotic dalbavancin on Staphylococcus aureus toxin production in vitroS. aureus toxin production levels were compared to those seen with the natural glycopeptide antibiotic vancomycin and with representative beta-lactam and oxazolidinone antibiotics. While neither dalbavancin nor vancomycin adversely affected toxin production, of these glycopeptide antibiotics, only dalbavancin significantly attenuated toxin production at subinhibitory concentrations. These findings support the recent success of dalbavancin for treatment of staphylococcal infections.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Staphylococcus aureus; subinhibitory antibiotics; toxin production

Mesh：

Substances：

Year:  2017        PMID： 28874375      PMCID： PMC5655096          DOI： 10.1128/AAC.01090-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

1.  Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model.

Authors:  Adam D Kennedy; Juliane Bubeck Wardenburg; Donald J Gardner; Daniel Long; Adeline R Whitney; Kevin R Braughton; Olaf Schneewind; Frank R DeLeo
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

Review 2.  Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.

Authors:  Ranjeet Prasad Dash; R Jayachandra Babu; Nuggehally R Srinivas
Journal:  Infect Dis (Lond)       Date:  2017-03-06

3.  Surveillance of dalbavancin potency and spectrum in the United States (2012).

Authors:  Ronald N Jones; Robert K Flamm; Helio S Sader
Journal:  Diagn Microbiol Infect Dis       Date:  2013-02-20       Impact factor: 2.803

4.  Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection.

Authors:  J Zimbelman; A Palmer; J Todd
Journal:  Pediatr Infect Dis J       Date:  1999-12       Impact factor: 2.129

5.  Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses.

Authors:  Adam R Spaulding; Ying-Chi Lin; Joseph A Merriman; Amanda J Brosnahan; Marnie L Peterson; Patrick M Schlievert
Journal:  Vaccine       Date:  2012-06-09       Impact factor: 3.641

6.  Pharmacokinetics and excretion of dalbavancin in the rat.

Authors:  Marco Cavaleri; Simona Riva; Anna Valagussa; Marco Guanci; Luigi Colombo; James Dowell; Martin Stogniew
Journal:  J Antimicrob Chemother       Date:  2005-03       Impact factor: 5.790

7.  Role of antibodies in protection elicited by active vaccination with genetically inactivated alpha hemolysin in a mouse model of staphylococcus aureus skin and soft tissue infections.

Authors:  Christopher P Mocca; Rebecca A Brady; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2014-02-26

8.  Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Pamela A Moise; George Sakoulas; Alan Forrest; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

9.  The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis.

Authors:  D L Stevens; A E Gibbons; R Bergstrom; V Winn
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

10.  Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review.

Authors:  Jason W Bennett; James S Lewis; Michael W Ellis
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
View more
  1 in total

1.  Antimicrobial and Antivirulence Action of Eugenia brejoensis Essential Oil in vitro and in vivo Invertebrate Models.

Authors:  Clovis Macêdo Bezerra Filho; Luís Cláudio Nascimento da Silva; Márcia Vanusa da Silva; Anders Løbner-Olesen; Carsten Struve; Karen Angeliki Krogfelt; Maria Tereza Dos Santos Correia; Maria Luiza Vilela Oliva
Journal:  Front Microbiol       Date:  2020-03-19       Impact factor: 5.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.